Health Canada grants Market Authorizaon for expanded use of Vertex’s TRIKAFTA

Vertex Pharmaceuticals announced that Health Canada has granted Market Authorization for the expanded use of PrTRIKAFTA to include children with cystic fibrosis ages 2 to 5 years who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. TRIKAFTA was previously approved by Health Canada for use in people with CF 6 years and older with at least one F508del mutation. “With this approval, approximately 330 Canadian children are for the first time eligible for a medicine that treats the underlying cause of their CF,” said Michael Siauw, General Manager at Vertex Pharmaceuticals (Canada) Incorporated. “We are working closely with private and provincial payers to secure coverage as quickly as possible for this expanded indication of TRIKAFTA.”